The votes are in... We’re thrilled to announce the nominees for #NEVYs24! This year’s event will celebrate 60+ companies that represent New England’s best in Tech, Tough Tech, Healthcare IT, Life Science, & MedTech. Meet the nominees here: bit.ly/4edfMRp #NEVYsSurvivor

We're thrilled to announce that CereVasc has been recognized by The New England Venture Capital Association as a nominee for the Emerging MedTech Company of the Year at the 12th Annual #NEVYs24! We look forward to joining our fellow innovators and celebrating #NEVYsSurvivor at the House of Blues on Dec 5th.

Minimally Invasive Procedure Making Treatment Possible for More People with Normal Pressure Hydrocephalus | By Dan Levangie, President and CEO of CereVasc infomeddnews.com/dan-levangie-1… via Medical Device News Magazine

Do your patients experience shuffling feet, cognitive impairment, or incontinence? These symptoms may be normal pressure #hydrocephalus and may prequalify your patients for the STRIDE #clinicaltrial—evaluating the #endovascular eShunt® system. Learn more: STRIDEclinicaltrial.com

Today we announced enrollment of the first patient in the STRIDE clinical trial of the eShunt® System for normal pressure hydrocephalus. Learn more about this unique study with clinical trial site locations in the United States and around the world. prnewswire.com/news-releases/…

.CereVasc has reported initial results from its pilot U.S. FDA-approved IDE clinical study of the eShunt system in the treatment of elderly patients with normal-pressure hydrocephalus charles matouk Charles Matouk neuronewsinternational.com/cerevasc-annou…

Team Montefiore Neurointerventional Surgery enrolled another patient in the @cerevasc pilot trial for the E-shunt, an endovascular treatment for NPH 🧠💦 🙏🏻🙏🏻🙏🏻 @circleowillis Montefiore Radiology MMC/AECOM Neurosurg Montefiore-Einstein Neurology Montefiore Health System

📣 In Case You Missed It: Dr. Ivan Lylyk joined us for GNI Grand Rounds to share his experience with the eShunt — a breakthrough in minimally invasive hydrocephalus treatment. 🧠 Explore how this innovation is reshaping CSF management and improving patient outcomes. 🎥 Now

We are excited to announce we received our second Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for the eShunt System. The Breakthrough Device Designation is for the treatment of communicating hydrocephalus in pediatric patients aged 12 and

Happy to be a part of this trial and get to work with such a great team!!

We all want hydrocephalus treatment that isn't brain surgery. Diana Gray, CEO at HA speaks with Dr. Charles Matouk from Yale University about the eShunt System - a minimally invasive treatment that could revolutionize how #hydrocephalus is managed. 📹 youtu.be/R7QYnoNMXXg CereVasc

Doctors at Baptist Health may be on the vanguard of addressing normal pressure hydrocephalus, a condition that affects 800,000 older Americans. A shunt system that's minimally invasive & promotes faster recovery, courtesy of CereVasc: tinyurl.com/29h4frx9 Hydrocephalus Assoc.

🚀 Breaking new ground in hydrocephalus treatment! 🌟 The eShunt System by CereVasc, featured in JNIS, offers an innovative endovascularly implantable cerebrospinal fluid shunt. Dive into the technical video for a step-by-step guide, key anatomic insights, and strategies to

Billy Joel has NPH. It is an uncommon condition of the elderly causing 3Bs. Balance (gait dysfunction), Brain (memory problems), Bladder (urinary incontinence). Traditionally treated with VP shunt. There’s a new game in town. The e-shunt. CereVasc Minimally invasive and

The STRIDE clinical trial is evaluating the safety and efficacy of the investigational eShunt® System—an endovascular approach to normal pressure hydrocephalus (NPH) treatment. Ivan Lylyk, MD, and Pedro Lylyk, MD, explain the trial’s significance and how the eShunt System differs

Your patients aged 60+ years with normal pressure hydrocephalus (NPH) may be right and ready for the STRIDE clinical trial—a study evaluating a new endovascular shunt. Watch to learn more about eligibility requirements. nphstridestudy.com/for-hcps.html?…

🚨 Study Approved in Canada! STRIDE trial is launching to study the eShunt System — an endovascular alternative to VP shunts for normal pressure hydrocephalus (NPH). 👥 Now enrolling potential candidates 📩 [email protected] RADIS lab Neurovascular Center @ St. Michael's Hospital St. Michael's Hospital Foundation

Navin had trouble walking, remembering, and needed help with daily tasks—signs of normal pressure hydrocephalus (NPH), caused by fluid buildup in the brain. A new study helped treat his condition without major surgery. Now he walks 3–4 miles a day! #URochesterResearch

With 18 active sites and more coming soon, the STRIDE clinical trial is the largest study in the treatment of normal pressure hydrocephalus (NPH). It is evaluating the first endovascular treatment approach for people with NPH. Watch to find a nearby trial site.

The STRIDE clinical trial is evaluating the safety and efficacy of the eShunt System®—a minimally invasive treatment for normal pressure hydrocephalus (NPH). During a recent webinar, Ricardo Hanel, MD, PhD, explained the procedure and how the device works. Learn More: